CD4 and cancer: Changes in immune response markers, such as reduced CD4+ T cells, impaired NK cell function, and immune checkpoint molecules like programmed cell death protein 1 (PD‐1), programmed death‐ligand 1 (PD‐L1), and lymphocyte activation gene 3 (LAG3), have been implicated in cancer progression [12].